1. Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program. Issue 2 (10th January 2023) Authors: McLaughlin, P; Grillo-López, A J; Link, B K; Levy, R; Czuczman, M S; Williams, M E; Heyman, M R; Bence-Bruckler, I; White, C A; Cabanillas, F; Jain, V; Ho, A D; Lister, J; Wey, K; Shen, D; Dallaire, B K Journal: Journal of clinical oncology Issue: Volume 41:Issue 2(2023) Page Start: 154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗